Women's Sexual Health: Libido, Pain, and Common Concerns
Women's sexual health encompasses a range of physiological and psychological domains, including sexual desire, arousal, lubrication, orgasm, and the presence or absence of pain during sexual activity. The Office on Women's Health (OWH) identifies sexual dysfunction as a clinically recognized area affecting women across all life stages, from reproductive years through menopause and beyond. Understanding these concerns within a structured framework helps distinguish normal variation from conditions requiring clinical evaluation.
Definition and scope
Sexual health, as defined by the World Health Organization (WHO), is a state of physical, emotional, mental, and social well-being in relation to sexuality — not merely the absence of disease or dysfunction. Within that framework, the clinical classification system most widely used in the United States is the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), published by the American Psychiatric Association, which organizes female sexual dysfunctions into 4 primary diagnostic categories:
- Female Sexual Interest/Arousal Disorder (FSIAD) — persistent or recurrent absence or reduction in sexual interest and arousal
- Female Orgasmic Disorder — marked delay in, infrequency of, or absence of orgasm, or reduced intensity
- Genito-Pelvic Pain/Penetration Disorder (GPPPD) — persistent difficulties with vaginal penetration, vulvovaginal or pelvic pain, fear or anxiety, or tightening of pelvic floor muscles
- Substance/Medication-Induced Sexual Dysfunction — dysfunction directly attributable to a pharmacological agent
The National Institutes of Health (NIH) estimates that sexual dysfunction affects approximately 43 percent of women in the United States at some point in their lives (NIH, Journal of the American Medical Association, Laumann et al., 1999). Scope extends beyond intercourse to encompass self-image, relationship function, hormonal status, and neurological integrity. For broader context on how these concerns fit within the regulatory and clinical landscape, see Women's Sexual Health on the main index.
How it works
Sexual response in women involves 4 overlapping physiological phases described in the Basson Circular Model (2001), which updated the earlier Masters-Johnson linear model to reflect the importance of emotional intimacy and subjective arousal in triggering desire. The phases — receptivity, arousal/desire, arousal with or without desire, and emotional and physical satisfaction — are not strictly sequential.
Neurological and hormonal mechanisms include:
- Estrogen maintains vaginal epithelial thickness, lubrication, and clitoral sensitivity. Declining estrogen at menopause directly reduces lubrication and tissue elasticity, a condition classified as Genitourinary Syndrome of Menopause (GSM) by the North American Menopause Society (NAMS).
- Testosterone contributes to libido in women, though it circulates at concentrations roughly 10–15 times lower than in men (Endocrine Society Clinical Practice Guidelines).
- Dopamine and serotonin pathways modulate sexual motivation. Selective serotonin reuptake inhibitors (SSRIs) — among the most commonly prescribed antidepressants in the U.S. — are documented to reduce libido and delay or inhibit orgasm in a substantial proportion of users (FDA drug labeling requirements, 21 CFR Part 201).
Pelvic floor anatomy plays a direct role in sexual pain disorders. Hypertonicity — excessive tension — of the levator ani and related muscles underlies vaginismus and contributes to dyspareunia. Pelvic floor health is an interrelated clinical domain addressed separately in this network. The FDA has cleared pelvic floor physical therapy referrals and biofeedback devices as treatment modalities for these conditions.
Common scenarios
Hypoactive Sexual Desire: The most prevalent sexual complaint among women presenting to clinicians, HSDD (now reclassified under FSIAD in DSM-5) involves persistently low desire causing personal distress. Two FDA-approved pharmacological agents exist for premenopausal women with this diagnosis: flibanserin (Addyi), approved in 2015, and bremelanotide (Vyleesi), approved in 2019 (FDA Drug Approvals).
Dyspareunia and Vulvodynia: Painful intercourse affects an estimated 10–20 percent of women at some point, per the American College of Obstetricians and Gynecologists (ACOG). Vulvodynia — chronic vulvar pain without identifiable cause — is classified by the International Society for the Study of Vulvovaginal Disease (ISSVD) into localized and generalized subtypes. Conditions such as endometriosis and uterine fibroids frequently co-present with deep dyspareunia.
Genitourinary Syndrome of Menopause (GSM): Affecting an estimated 50 percent of postmenopausal women (NAMS Position Statement, 2023), GSM produces vaginal dryness, burning, irritation, and pain during intercourse. Treatment options include local vaginal estrogen, ospemifene (an oral selective estrogen receptor modulator), and the non-hormonal vaginal DHEA compound prasterone. See menopause symptoms and management for the broader hormonal context.
Orgasmic Disorders: Primary anorgasmia (never having experienced orgasm) and secondary anorgasmia (loss of previously present orgasmic capacity) are distinguished diagnostically. Secondary anorgasmia is commonly medication-related or associated with pelvic nerve damage from conditions such as multiple sclerosis or diabetes; see diabetes and women's health.
Decision boundaries
Distinguishing normal variation from clinically significant dysfunction requires applying 2 threshold criteria defined in DSM-5: the symptoms must persist for a minimum of approximately 6 months, and they must cause marked distress or interpersonal difficulty. Situational dysfunction — occurring only in specific contexts — is distinguished from generalized dysfunction.
Comparison: Physiological vs. Psychogenic etiology
| Feature | Physiological | Psychogenic |
|---|---|---|
| Onset pattern | Gradual, progressive | Often sudden or situational |
| Hormonal markers | Abnormal (low estrogen, low testosterone) | Within normal reference ranges |
| Associated diagnoses | Endocrine, neurological, or anatomic conditions | Anxiety, depression, trauma history |
| Response to lubricants | Partial relief in GSM | Variable |
| Pelvic floor involvement | Hypertonicity or atrophy | Hypertonicity without atrophy |
Referral pathways vary by presentation. ACOG guidelines recommend that primary care providers screen for sexual concerns during well-woman visits and refer to specialists — including gynecologists, pelvic floor physical therapists, certified sex therapists, or endocrinologists — based on the predominant etiology. The regulatory context for women's health page details how federal agencies, including FDA and the Office on Women's Health, structure oversight of diagnostic and treatment frameworks in this area.
Mental health factors, including a history of sexual trauma, are independently associated with sexual dysfunction and require assessment distinct from biomedical workup. Mental health and women is addressed as a standalone clinical domain within this network.
References
- Office on Women's Health (OWH) — Sexual Health
- World Health Organization — Sexual Health
- American Psychiatric Association — DSM-5
- North American Menopause Society (NAMS) — Genitourinary Syndrome of Menopause Position Statement
- American College of Obstetricians and Gynecologists (ACOG) — Sexual Dysfunction
- Endocrine Society Clinical Practice Guidelines
- U.S. Food and Drug Administration — Drug Approvals and Databases
- National Institutes of Health — Laumann et al., JAMA 1999
- Code of Federal Regulations, 21 CFR Part 201 — Drug Labeling
- International Society for the Study of Vulvovaginal Disease (ISSVD)
The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)